LNP023

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

C3 Glomerulopathy

Conditions

C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis

Trial Timeline

Oct 3, 2019 → May 30, 2036

NCT ID

NCT03955445

About LNP023

LNP023 is a phase 3 stage product being developed by Novartis for C3 Glomerulopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03955445. Target conditions include C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06934967	Phase 3	Recruiting	Oct 28, 2025	Dec 19, 2031	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06931691	Pre-clinical	Recruiting	Jun 10, 2025	Apr 20, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT04557462	Phase 3	Recruiting	Sep 20, 2021	Oct 25, 2032	Primary IgA Nephropathy
NCT03955445	Phase 3	Recruiting	Oct 3, 2019	May 30, 2036	C3 Glomerulopathy
NCT03896152	Phase 2	Completed	Apr 5, 2019	Feb 9, 2022	Paroxysmal Nocturnal Hemoglobinuria
NCT03832114	Phase 2	Completed	Feb 20, 2019	Apr 23, 2021	Glomerulonephritis
NCT03373461	Phase 2	Completed	Feb 7, 2018	Jun 22, 2021	IgA Nephropathy

Competing Products

5 competing products in C3 Glomerulopathy

See all competitors

Product	Company	Stage	Hype Score
Iptacopan	Novartis	Pre-clinical	30
Avacopan + Avacopan Matching Placebo	Amgen	Phase 2	35
ARO-C3 + Placebo	Arrowhead Pharmaceuticals	Phase 1/2	29
BCX9930	BioCryst Pharmaceuticals	Phase 2	21
OMS906 study drug	Omeros Corporation	Phase 2	36